The collaboration between U.Va. Health and a local company developed a PCR test that will help identify whether or not a patient will have a severe reaction to COVID-19
As doctors and public health officials brace for a possible fall coronavirus surge, one of the challenges continues to be predicting who will have a mild, moderate or severe case of COVID-19.
Will I get severe ill if infected with COVID-19? This new genomic test can identify patients at high risk for poor outcomes.
After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma.
Dermatologists routinely do skin biopsies to figure out what’s wrong with their patients. They study tissue under a microscope – looking at the structure of cells, but a Charlottesville company says doctors could treat disease more precisely by looking at genetics.